16 MARCH 2020
Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has partnered with the Beth Israel Deaconess Medical Center (BIDMC) to advance Covid-19 vaccine development.
The partners started pre-clinical testing of different vaccine prospects. The aim is to select a vaccine candidate for clinical trials by the end of this month.
Janssen expects to launch a Phase I clinical trial by the end of the year. The company is also working to upscale production and manufacturing capacities to meet public vaccination needs globally.
J&J chief scientific officer Paul Stoffels said: “It is critical to work with the best scientific minds as we look to rapidly identify and develop solutions to the Covid-19 outbreak. We are grateful for talented and experienced collaboration partners like Dan Barouch and his team at BIDMC.
